Small Cap Feast
Small Cap Feast – 05 March 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 908
Total number of AIM Companies trading: 837*
* As at 27 February 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 27 February 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 161*
Total number of Standard List Companies trading: 142*
* As at 27 February 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
DWF, a global legal business, expects to raise primary gross proceeds of approximately £75m. Due March
US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 20 March
Techniplas –global producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient. FYDec17 rev $515m.
Crossword Cybersecurity* (CCS.L) 335p £15.68m
Crossword Cybersecurity, the technology commercialisation company focusing exclusively on the cyber security sector, announced that it has signed an agreement with Nuvia Limited for the use of Crossword’s secure Third-party Assurance platform, Rizikon Assurance.
Nuvia is an international engineering, project management and service provider. In the UK and internationally, they have been at the forefront of the nuclear industry and have developed a reputation for safe, high quality delivery. Their operations include; turn-key design and build, consultancy, waste management, land remediation, decommissioning and radiation protection.
Nuvia benefits from being part of Soletanche Freyssinet, a world leader in specialised civil and geotechnical engineering, and a wholly owned subsidiary of VINCI, the world’s largest integrated concessions and construction group.
Rizikon Assurance is a secure, encrypted portal used by organisations to assure their third parties and suppliers. It contains standard questionnaires on subjects such as cyber security, GDPR, supplier on-boarding, modern slavery and anti-bribery & corruption, and also supports the customer’s own question sets and scoring approaches. It improves the scalability, security and auditability of third party assurance and due diligence via automation, centralisation and encryption.
Integumen* (SKIN.L) 1.45p £7.03m
Integumen, announced that the Company has entered into an agreement with Cellulac Limited to acquire hi-tech laboratory test equipment, to be installed into the enlarged Labskin UK laboratories in York.
The new laboratory, recently completed, will house this range of specialised test equipment, which includes Gas Chromatography-Mass Spectrometry and High-Performance Liquid Chromatography units and ancillary equipment.
This extends Labskin’s capability beyond skin care test services by monitoring the molecular growth and odour causing bacteria on lab-grown human skin. The cost of the Equipment is £400,000 which will be satisfied by the issue of a loan note (see below).
The consideration comprises a two-year nil coupon convertible, redeemable loan note in the sum of £400,000. The Loan Note is secured on the Equipment and is repayable on the earliest of the following events:
February 26, 2021;
the completion of a transaction whereby any person or group of persons acting in concert acquires a controlling interest of 50% or more in the Company; or
the sale of all or substantially all of the assets of the Company thereof (whether in a single transaction or a series of transactions).
It has been agreed that, in the six months following the acquisition of the Equipment, any costs of service, calibration and commission in excess of £20,000 will be offset against the Loan Note principal.
Bilby (BILB.L) 42p £26.76m
Bilby, a leading gas heating, electrical and building services provider, announced the following trading update for year ending 31 March 2019.
The second half has seen a continuation of certain challenging customer circumstances originally announced in the interim statement in Dec 2018.
As previously announced P&R, one the five companies within the Group, gave notice of termination of its contract to supply building maintenance services for MoD properties and is still subject to dispute and resolution proceedings. Additionally, delays to a major gas installation contract have continued and the Company remains in active discussion with the organisation regarding a resolution. As a result, P&R, through which the Company was undertaking both contracts, will now report a significant loss for the full year. Accordingly, the Board expects the trading losses and associated write offs at the division to lead to the Group reporting a positive EBITDA of between £2m to £3m before non-underlying restructuring costs and losses associated with the termination of the contract for MoD properties. Whilst the future of gas services within the P&R division is now being reviewed, it remains a core service for the rest of Group.
The other divisions of the Group continue to trade well and in line with management expectations for the current year.
EU Supply (EUSP.L) 10.5p £7.53m
EU Supply, the e-procurement software provider, announced strong demand in its target markets for 2019.
In particular, the Company has been awarded the following contracts with new clients in both Denmark and Germany:
A new procurement service provider in Denmark, which is live with the Company’s CTMTMsolution.
Two new clients in the Danish public sector, which were awarded following competitive tender processes, both of which migrated from a competitor’s solution and are live with the Company’s CTMTM solution.
Two new clients in Germany, one of which is now live with Company’s CTMTM solution.
In addition, the Group has configured its solution for use in the tendering process for the Femern Tunnel, which is proposed to connect Denmark and Germany and is believed will become the longest combined rail and road tunnel worldwide. The overall construction phase is expected to be 8 to 9 years. Some of Europe’s largest contractors and contract managers are expected to be involved. The first tenders for the project have been published on the Company’s CTMTM platform.
Watkin Jones (WJG.L) 215p £565.42m
Watkin Jones, a leading UK developer and constructor of multi-occupancy residential property assets, with a focus on the student accommodation and build to rent sectors, announced that the Group has acquired a prime development site in Woking town centre from McKay Securities PLC with capacity for approximately 350 build to rent apartments on a subject to planning basis.
The proposed development will comprise a purpose-designed build to rent scheme in which residents will benefit from high quality accommodation and outstanding communal facilities, including a resident’s lounge and roof terrace. The scheme is also expected to include new retail and leisure space. The development is expected to deliver a margin in line with target returns and is targeted for completion in FY 2024.
SimplyBiz (SBIZ.L) 192p £138.03m
SimplyBiz, the leading independent provider of compliance and business services to financial advisers and financial institutions in the UK, announced its audited consolidated results for the twelve months ended 31 Dec 2018.
Group Revenue up 15% to £50.7m (FY17: £44.1m)
Adjusted EBITDA up 19.7% to £11.4m (FY17: £9.5m)
Adjusted EBITDA margin increased to 22.5% (FY17: 21.7%)
Operating profit of £6.8m (FY17: £8.8m) after charging IPO related costs of £3.6m
Adjusted profit after tax increased 61.6% to £8.6m
Adjusted EPS increased by 28.2% to 11.92p
Net debt reduced from £1.6m at date of listing to net cash of £6.4m at 31 Dec 2018 (31 Dec 2017: net debt of £23m)
Final dividend proposed of 2.05p per share, in respect of the nine months trading to 31 Dec, post IPO, as per the stated intention in the admission document. Total dividend of 3.03p per share
Fox Marble (FOX.L) 8.75p £18.78m
Fox Marble announced the resumption of production after the usual winter shut down in our Prilep quarry in Northern Macedonia. The quarry, which contains white marble marketed as Alexandrian White, is now also producing substantial quantities of Alexandrian Blue from a newly developed section on the east side of the site. The quarry is expected to benefit from the deployment of additional equipment to significantly increase production levels to satisfy growing demand.
In Feb Fox Marble sold, and received payment for, 400 tonnes of Alexandrian White blocks to a new customer. The customer is shipping these blocks to their facility in Drama in Northern Greece for processing. This customer was responsible for supplying similar material to the Sheik Zayed Grand Mosque in Abu Dhabi and has indicated their intention to purchase additional quantities of this marble on a regular basis throughout the year.
Mpac (MPAC.L) 137p £27.23m
Mpac, the global packaging solutions group, announced its results for the 12 months to 31 Dec 2018
Continued progress on the Group’s strategic initiatives. Increase in order intake of 4% compared to 2017 and a closing order book 16% higher than at the start of 2018. Sales growth of 9% to £58.3m (2017: £53.4m).
Underlying PBT of £1.4m (2017: £1.1m)
Non-underlying GMP equalisation charge of £7.3m (2017: nil)
Statutory loss before tax from continuing activities of £7.4m (2017: profit £4.3m)
Underlying EPS of 4.5p (2017: 4.2p)
Basic loss per share from continuing activities of 30.1p (2017: earnings of 12.2p)
Net cash of £27m (2017: £29.4m)
The Board has decided not to recommend payment of a final dividend
Craneware (CRW.L) 2,625p £710.19m
Craneware, the market leader in Value Cycle solutions for the US healthcare market, announced its unaudited results for the six months ended 31 Dec 2018.
Revenue increased 15% to $35.8m (H1 2018: $31.1m)
Adjusted EBITDA increased 20% to $11.6m (H1 2018: $9.7m)
PBT increased 7% to $9.3m (H1 2018: $8.7m)
Adjusted basic EPS increased 19% to 30.2 cents per share (H1 2018: 25.4 cents per share)
Cash position of $38.7m (H1 2018: $52.2m), following significant returns to shareholders and investments in the period
Proposed interim dividend increased 10% to 11p (H1 2018: 10p per share)
CIP Merchant Capital (CIP.L) 68.5p £37.68m
CIP Merchant Capital announced that it has acquired a further 2,500 shares in Orthofix Medical Inc. (formerly Orthofix International N.V.), a NASDQ listed medical devices company, for a total consideration of approximately $0.15m.
Following the acquisition, CIP Merchant Capital is now interested in 97,000 shares of Orthofix.
In the year ended 31 Dec 2018 Orthofix had net income of $13.8m and as at 31 Dec 2018 had net assets of $335.4m.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.